© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model
Affiliations of authors: Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Baltimore, MD (BJL, DJ, VH, AT, AMB); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (NM, JR); Division of Biostatistics, University of Maryland Greenebaum Cancer Center, Baltimore (OGG)
Correspondence to: Angela M. Brodie, PhD, Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Rm. 580G, 685 West Baltimore St., Baltimore, MD 21201 (e-mail abrodie{at}umaryland.edu)
Background: The antiestrogen tamoxifen has potent activity against estrogen receptor–positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability. To determine the optimal way to use letrozole and tamoxifen, we studied their effects on a breast tumor xenograft model, MCF-7Ca, that is responsive to both antiestrogens and aromatase inhibitors. Methods: Female ovariectomized BALB/c athymic nude mice carrying xenograft tumors were treated daily subcutaneously with one of the following first-line therapies for varying durations: no drug (control), tamoxifen (100 µg/day) alone, letrozole (10 µg/day) alone, both drugs at the same time, or alternating 4-week courses of each drug (beginning with a course of tamoxifen or beginning with a course of letrozole). Tumor volumes and weights were estimated using linear mixed-effects models. The time to tumor doubling was calculated, and tumor weights in the treatment groups were compared, with adjustments for multiple comparisons being made with either Tukey’s or Dunnett’s procedure. Second-line therapies (with tamoxifen, letrozole, or fulvestrant) were initiated when tumors doubled in size under first-line therapies. All statistical tests were two-sided. Results: The times for doubling of tumor volume were as follows: control, 3–4 weeks; tamoxifen alone, 16 weeks; tamoxifen alternating with letrozole, 17–18 weeks; tamoxifen plus letrozole, 18 weeks; letrozole alternating with tamoxifen, 22 weeks; letrozole alone, 34 weeks. First-line treatment with letrozole was superior to treatment with tamoxifen alone or with the two drugs combined (at week 16, both P<.001). Alternating tamoxifen and letrozole and alternating letrozole and tamoxifen were also not as effective as letrozole alone (at week 16, P = .002 and P<.001, respectively). Tumors progressing on tamoxifen remained sensitive to second-line therapy with letrozole compared with those remaining on tamoxifen at the end of treatment (week 28, P<.001), whereas tumors progressing on letrozole were unaffected by second-line treatment with the antiestrogens tamoxifen or fulvestrant. Conclusions: First-line letrozole therapy extends time for tumor progression in this model relative to the other treatment regimens tested. However, further studies are needed to determine the most effective second-line therapy for tumors that progress on letrozole.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al. Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter? Oncologist, August 1, 2008; 13(8): 829 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Sabnis, L. F. Macedo, O. Goloubeva, A. Schayowitz, and A. M.H. Brodie Stopping Treatment Can Reverse Acquired Resistance to Letrozole Cancer Res., June 15, 2008; 68(12): 4518 - 4524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Crivellari, Z. Sun, A. S. Coates, K. N. Price, B. Thurlimann, H. Mouridsen, L. Mauriac, J. F. Forbes, R. J. Paridaens, M. Castiglione-Gertsch, et al. Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial J. Clin. Oncol., April 20, 2008; 26(12): 1972 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and B. W. O'Malley Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5815 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sabnis, O. Goloubeva, D. Jelovac, A. Schayowitz, and A. Brodie Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway Improves Response of Long-term Estrogen-Deprived Breast Cancer Xenografts to Antiestrogens Clin. Cancer Res., May 1, 2007; 13(9): 2751 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Belosay, A. M.H. Brodie, and V. C.O. Njar Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN/14-1) on Letrozole-Insensitive Breast Cancer Cells Cancer Res., December 1, 2006; 66(23): 11485 - 11493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Swain Aromatase Inhibitors -- A Triumph of Translational Oncology N. Engl. J. Med., December 29, 2005; 353(26): 2807 - 2809. [Full Text] [PDF]
|
|
|
|
|
|
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. M. Herrera, L. R. B. Ponce, P. D. Bagamasbad, B. D. VanPelt, T. Didishvili, and N. Ruiz-Opazo Embryonic lethality in Dear gene-deficient mice: new player in angiogenesis Physiol Genomics, November 17, 2005; 23(3): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Punglia, K. M. Kuntz, E. P. Winer, J. C. Weeks, and H. J. Burstein Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis J. Clin. Oncol., August 1, 2005; 23(22): 5178 - 5187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jelovac, G. Sabnis, B. J. Long, L. Macedo, O. G. Goloubeva, and A. M.H. Brodie Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole Cancer Res., June 15, 2005; 65(12): 5380 - 5389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jelovac, L. Macedo, O. G. Goloubeva, V. Handratta, and A. M.H. Brodie Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer Model Cancer Res., June 15, 2005; 65(12): 5439 - 5444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Sabnis, D. Jelovac, B. Long, and A. Brodie The Role of Growth Factor Receptor Pathways in Human Breast Cancer Cells Adapted to Long-term Estrogen Deprivation Cancer Res., May 1, 2005; 65(9): 3903 - 3910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brodie, D. Jelovac, L. Macedo, G. Sabnis, S. Tilghman, and O. Goloubeva Therapeutic Observations in MCF-7 Aromatase Xenografts Clin. Cancer Res., January 15, 2005; 11(2): 884s - 888s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jelovac, L. Macedo, V. Handratta, B. J. Long, O. G. Goloubeva, J. N. Ingle, and A. M. H. Brodie Effects of Exemestane and Tamoxifen in a Postmenopausal Breast Cancer Model Clin. Cancer Res., November 1, 2004; 10(21): 7375 - 7381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Nunez, D. Jelovac, L. Macedo, D. Berrigan, S. N. Perkins, S. D. Hursting, J. C. Barrett, and A. Brodie Effects of the Antiestrogen Tamoxifen and the Aromatase Inhibitor Letrozole on Serum Hormones and Bone Characteristics in a Preclinical Tumor Model for Breast Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5375 - 5380. [Abstract] [Full Text] [PDF]
|
|